Latest News about GSK
Recent news which mentions GSK
From Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
June 20, 2024
From Benzinga
From Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
From InvestorPlace
From InvestorPlace
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
June 06, 2024
From InvestorPlace
Tickers
GSK
From InvestorPlace
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
June 03, 2024
From Benzinga
From Benzinga
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
June 03, 2024
From Benzinga
From Benzinga
From Motley Fool
From Benzinga
Moderna Investors Just Got Some Bullish News
June 03, 2024
From Motley Fool
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
May 27, 2024
From Benzinga
From Benzinga
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
May 22, 2024
From Benzinga
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
May 21, 2024
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From InvestorPlace
From InvestorPlace
Is This a Setback for Moderna?
May 14, 2024
From Motley Fool
From Benzinga
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
May 10, 2024
From Benzinga
From Benzinga
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
May 08, 2024
From Benzinga
From InvestorPlace
Tickers
GSK
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.